Hulio

Hulio is a prescription subcutaneous injection that contains the biologic agent adalimumab. It is marketed in the European Union and listed without a specific strength in this summary. As a TNF‑alpha inhibitor, Hulio belongs to the immunosuppressant class and is used under medical supervision for several inflammatory disorders. The product is administered by injection and patients should follow the prescribed schedule while monitoring for adverse reactions.

Hulio (adalimumab) is indicated for the treatment of several chronic inflammatory and autoimmune conditions where suppression of tumor necrosis factor‑alpha is beneficial.

- Rheumatoid arthritis – moderate to severe disease unresponsive to conventional DMARDs - Psoriatic arthritis – active joint disease with skin involvement - Ankylosing spondylitis – axial skeletal inflammation in adults - Crohn’s disease – moderate to severe intestinal inflammation - Ulcerative colitis – extensive disease requiring systemic therapy - Plaque psoriasis – widespread plaques not controlled by topical agents - Hidradenitis suppurativa – chronic nodular lesions in typical areas

Adalimumab may cause a range of adverse reactions, most of which are mild to moderate, while a smaller number can be serious and require medical attention.

Common: - Injection site pain, redness, swelling, or bruising - Upper respiratory tract infections such as sinusitis, nasopharyngitis, or common cold - Headache of mild to moderate intensity - Nausea or decreased appetite - Mild skin rash, itching, or localized urticaria - Fatigue or general tiredness

Serious: - Serious infections including active tuberculosis, bacterial sepsis, opportunistic fungal infections, or viral reactivation - Reactivation of chronic hepatitis B virus infection, which may lead to liver inflammation - Malignancies such as lymphoma, leukemia, or non‑melanoma skin cancer observed during therapy - Severe allergic reactions including anaphylaxis, angioedema, or serum sickness‑like syndrome

Before starting Hulio, patients and clinicians should consider several precautionary measures to minimize risks and ensure safe use.

- Screen for active or latent tuberculosis and treat before therapy. - Evaluate for chronic infections such as hepatitis B, hepatitis C, or HIV and monitor during treatment. - Assess for a history of demyelinating disease, congestive heart failure, or recent malignancy. - Use caution in pregnant or breastfeeding women; safety data are limited. - Monitor complete blood counts and liver function tests regularly while on therapy.

Adalimumab can interact with other medicines, affecting its efficacy or increasing the risk of adverse events.

Avoid: - Live attenuated vaccines (e.g., measles, varicella) because immunosuppression may cause infection. - Concomitant use with other biologic agents targeting the immune system (e.g., abatacept, rituximab) due to heightened infection risk. - Concurrent use with strong immunosuppressants such as high‑dose corticosteroids may increase infection risk.

Use with caution: - Methotrexate or other disease‑modifying antirheumatic drugs (DMARDs) – may increase immunosuppression. - Antifungal agents such as azoles – may alter infection risk. - Cyclosporine or tacrolimus – additive immunosuppressive effect. - Interferon‑beta – potential for increased autoimmune reactions. - Vaccination with inactivated vaccines – response may be reduced, timing should be considered.